In contrast with previous studies that reported no mutations in TP53 [32], deep sequencing studies [22] are increasingly demonstrating that the deregulation of the p53 pathway is common in chemorefractory cHL patients, as it is well-established in other cancers. Here, TP53 is linked to cancer.